Scientists at RMW Cho Group Ltd. and Venner Shipley LLP have divulged chlorin K derivatives acting as photosensitizers reported to be used in photodynamic therapy (PDT) and photodynamic diagnosis of cancer.
Scientists at Aten Porus Lifesciences Pvt Ltd. and Avammune Therapeutics Inc. have synthesized double-stranded RNA-specific adenosine deaminase (ADAR; ADAR1; IFI-4) inhibitors reported to be useful for the treatment of cancer.
Di’ao Group Chengdu Pharmaceutical Co Ltd. has disclosed DNA-directed RNA polymerase, mitochondrial (POLRMT; MtRPOL) inhibitors reported to be useful for the treatment of cancer.
Applaud Medical Inc. continues to file for protection for aspects of its BRIO Enhanced Lithotripsy System, an acoustic enhancer technology which aims to eliminate ureteral stones quickly, affordably, and without the need for general anesthesia or a fluoroscopy procedure that may be conducted in a physician’s office and other non-hospital setting.
Shenyang Pharmaceutical University has identified serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.
Hainan Simcere Pharmaceutical Co. Ltd. has patented fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.
Tiger Biotherapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to a GTPase KRAS (mutant)-binding moiety through a linker.
RSS
